Overcoming Receptor Tyrosine Kinase mediated resistance to BRAF Inhibitors in metastatic melanoma, colorectal and lung cancers.

Grant number: 1042980 | Funding period: 2013 - 2017



The drug Vemurafenib results in good responses in melanoma patients. However, patients become resistant to treatment. We have identified specific receptors that can cause Vemurafenib resistance, which can be overcome by combination treatment with drugs to these receptors. We will assess melanoma patient samples for expression of these receptors which will be highly beneficial for selecting combination treatments to prevent drug resistance and ensure better prolonged outcomes.

Related publications (5)

University of Melbourne Researchers